BioSpace News Archive

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease was featured on a Fox Business News segment. Fox Business News reports: “INmune Bio CEO, President and acting CMO Dr. Raymond Tesi, M.D. talks about INmune Bio’s proposed phase two human trials of possible treatment of coronavirus patients using an ant

Transformative, a healthcare startup whose software predicts sudden cardiac arrest, announced that it has raised a $1.7 million seed round, led by Tera Ventures.

Bruker Corporation announced the launch of the FluoroType® SARS-CoV-2 plus next-generation 6-plex PCR assay for the highly specific detection of the SARS-CoV-2 virus, which causes the respiratory and systemic disease COVID-19.

Venatorx Pharmaceuticals announced that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services to advance a novel series of Penicillin Binding Protein Inhibitors targeting multi-drug resistant Acinetobacter baumannii through Phase 1 clinical testing.

Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific Daylight Time to discuss the financial results and recent business developments.

-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning -Since the Start of COVID-19, the FDA has Recalled More Than 75 Contaminated Hand Sanitizers Due to Risk of Methanol Poisoning -DS-100 is Eton’s Fifth Drug Application Under FDA Review and Second Orphan Application DEER PARK, Ill., July 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced AMAG and Palatin Technologies, Inc. have mutually terminated the January 2017 license agreement pursuant to which AMAG was granted exclusive rights to develop and commercialize Vyleesi® (bremelanotide), a melanocortin receptor agonist indicated for th

VitalHub Corp. is pleased to announce they have been selected by the National Health Service as one of two vendors to be included within the new NHS Framework Agreement.

Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Company ), the Company developing New Classes of Synthetic Anti-infectives, today announced that it will be delivering the Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress from the 8th – 9th October 2020. Due to the global pandemic, the conference will be held entirely virtually. The two-day World AMR Congress is the largest commercially focused conference with AMR at i

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced the appointment of Joseph Shulman as the Company’s Senior Vice President, Technical Operations. Mr. Shulman brings more than 20 years of industry experience in chemistry, manufacturing and controls (CMC) technical development, operations, and program